• IgG1 antibody demonstrates efficacy, tolerability for patients with myasthenia gravis

    1 month ago - By Healio

    Efgartigimod, a human IgG1 antibody designed to decrease pathogenic IgG autoantibody levels, demonstrated efficacy and tolerability among patients with generalized myasthenia gravis, according to findings published in The Lancet Neurology.
    “Although there are treatment options available to patients with generalized myasthenia gravis, they are frequently burdensome, have substantial side-effects, do not alleviate symptoms, or are reserved for refractory patients,” the researchers wrote. “ADAPT was the largest clinical trial in patients with generalized myasthenia gravis and
    Read more ...